Trial Profile

Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of an Ad26.Mos4.HIV and CH505 TF chTrimer (Env) Combination to Mimic Acute HIV Viral Replication Kinetics in Healthy Adults

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26 Mos4 HIV (Primary) ; CH 505 NP (Primary) ; Monophosphoryl lipid A; QS 21
Indications HIV infections
Focus Adverse reactions

23 Apr 2025 Arms increased from 2 to 4. Experimental arms Ad26.Mos4.HIV and CH505 TF chTrimer + ALFQ [Arm 2a] and CH505 TF chTrimer + ALFQ [Arm 2b] added newly.
23 Apr 2025 Planned number of patients changed from 50 to 78.
23 Apr 2025 Planned End Date changed from 1 Sep 2025 to 1 Jun 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com